Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Interventional × reparixin × Clear all
NCT05835466 2026-05-06

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Icahn School of Medicine at Mount Sinai

Phase 2 Recruiting
10 enrolled
Myeloid

Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡